54
Participants
Start Date
July 9, 2020
Primary Completion Date
November 28, 2020
Study Completion Date
January 4, 2021
Crizanlizumab
Crizanlizumab 5.0 mg/kg in 100 ml IV once.
0.9% saline
0.9% saline 100 ml IV once.
Johns Hopkins Hospital, Baltimore
Collaborators (1)
Novartis
INDUSTRY
Socar Research SA
NETWORK
Brigham and Women's Hospital
OTHER
Johns Hopkins University
OTHER